首页 > 最新文献

Cancer Epidemiology最新文献

英文 中文
Cancer incidence after an open cut coal mine fire 露天煤矿火灾后的癌症发病率
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-29 DOI: 10.1016/j.canep.2024.102651
Pei Yu , Caroline X. Gao , Catherine L. Smith , Sherene Loi , Natasha Kinsman , Jillian F. Ikin , Yuming Guo , Malcolm R. Sim , Michael J. Abramson , Tyler J. Lane

Using population-level cancer diagnosis data, we compared cancer incidence in locations affected by smoke from a six week-long open cut coal mine fire in regional Victoria, Australia, up to seven years following the event. There was no detectable effect on cancer incidence overall. While several subgroups exhibited changes, these were more likely due to statistical chance rather than real effects. These findings may be limited by low statistical power and short duration of follow up. To confirm the influence of open cut coal mine fires on cancer incidence, further research and an extended follow-up duration are necessary.

我们利用人口层面的癌症诊断数据,比较了澳大利亚维多利亚地区一次长达六周的露天煤矿大火烟雾影响地区在事件发生后七年内的癌症发病率。总体而言,癌症发病率没有受到任何影响。虽然有几个亚群出现了变化,但这些变化更可能是由于统计上的偶然性,而不是真正的影响。这些发现可能受限于较低的统计能力和较短的随访时间。为了证实露天煤矿火灾对癌症发病率的影响,有必要开展进一步的研究并延长随访时间。
{"title":"Cancer incidence after an open cut coal mine fire","authors":"Pei Yu ,&nbsp;Caroline X. Gao ,&nbsp;Catherine L. Smith ,&nbsp;Sherene Loi ,&nbsp;Natasha Kinsman ,&nbsp;Jillian F. Ikin ,&nbsp;Yuming Guo ,&nbsp;Malcolm R. Sim ,&nbsp;Michael J. Abramson ,&nbsp;Tyler J. Lane","doi":"10.1016/j.canep.2024.102651","DOIUrl":"10.1016/j.canep.2024.102651","url":null,"abstract":"<div><p>Using population-level cancer diagnosis data, we compared cancer incidence in locations affected by smoke from a six week-long open cut coal mine fire in regional Victoria, Australia, up to seven years following the event. There was no detectable effect on cancer incidence overall. While several subgroups exhibited changes, these were more likely due to statistical chance rather than real effects. These findings may be limited by low statistical power and short duration of follow up. To confirm the influence of open cut coal mine fires on cancer incidence, further research and an extended follow-up duration are necessary.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102651"},"PeriodicalIF":2.4,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124001309/pdfft?md5=6ecaac26017ffde4b1be0b8870ab9d5d&pid=1-s2.0-S1877782124001309-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142094605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung cancer mortality trends and disparities: A cross-sectional analysis 1999–2020 肺癌死亡率趋势和差异:1999-2020 年横截面分析
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-27 DOI: 10.1016/j.canep.2024.102652
Sabrina Soin , Ramzi Ibrahim , Rebecca Wig , Numaan Mahmood , Hoang Nhat Pham , Enkhtsogt Sainbayar , João Paulo Ferreira , Roger Y. Kim , See-Wei Low

Background

Lung cancer remains a leading cause of morbidity and mortality in the United States. Given the importance of epidemiological insight on lung cancer outcomes as the foundation for targeted interventions, we aimed to examine lung cancer death trends in the United States in the recent 22-year period, exploring demographic disparities and yearly mortality shifts.

Methods

Mortality information was obtained from the CDC Wide-ranging Online Data for Epidemiologic Research database from the years 1999–2020. Demographic information included age, sex, race or ethnicity, and area of residence. We performed log-linear regression models to assess temporal mortality shifts and calculated average annual percentage change (AAPC) and compared age-adjusted mortality rates (AAMR) across demographic subpopulations.

Results

A total of 3,380,830 lung cancer deaths were identified. The AAMR decreased from 55.4 in 1999-31.8 in 2020 (p<0.001). Males (AAMR 57.6) and non-Hispanic (NH) (AAMR 47.5) populations were disproportionately impacted compared to females (AAMR 36.0) and Hispanic (AAMR 19.1) populations, respectively. NH Black populations had the highest AAMR (48.5) despite an overall reduction in lung cancer deaths (AAPC −3.3 %) over the study period. Although non-metropolitan regions were affected by higher mortality rates, the annual decrease in mortality among metropolitan regions (AAPC −2.8 %, p<0.001) was greater compared to non-metropolitan regions (AAPC −1.7 %, p<0.001). Individuals living in the Western US (AAPC −3.4 %, p<0.001) experienced the greatest decline in lung cancer mortality compared to other US census regions.

Conclusions

Our findings revealed lung cancer mortality inequalities in the US. By contextualizing these mortality shifts, we provide a larger framework of data-driven initiatives for societal and health policy changes for improving access to care, minimizing healthcare inequalities, and improving outcomes.

背景肺癌仍然是美国发病和死亡的主要原因。鉴于流行病学对肺癌结果的洞察力是进行有针对性干预的重要基础,我们旨在研究美国最近 22 年的肺癌死亡趋势,探索人口统计学差异和每年的死亡率变化。人口统计学信息包括年龄、性别、种族或民族以及居住地区。我们建立了对数线性回归模型来评估死亡率的时间变化,并计算了年均百分比变化(AAPC),比较了不同人口亚群的年龄调整死亡率(AAMR)。年龄调整死亡率从 1999 年的 55.4 降至 2020 年的 31.8(p<0.001)。与女性(AAMR 36.0)和西班牙裔(AAMR 19.1)相比,男性(AAMR 57.6)和非西班牙裔(NH)(AAMR 47.5)人群受到的影响更大。尽管在研究期间肺癌死亡人数总体上有所下降(AAPC -3.3%),但北卡罗来纳州黑人的 AAMR 最高(48.5)。虽然非大都市地区受到较高死亡率的影响,但与非大都市地区(AAPC -2.7%,p<0.001)相比,大都市地区死亡率的年降幅更大(AAPC -2.8%,p<0.001)。与美国其他人口普查地区相比,生活在美国西部(AAPC -3.4%,p<0.001)的人的肺癌死亡率下降幅度最大。我们的研究结果揭示了美国肺癌死亡率的不平等现象。通过对这些死亡率变化的背景进行分析,我们提供了一个更大的数据驱动倡议框架,以促进社会和卫生政策的改变,从而改善医疗服务的可及性,最大限度地减少医疗不平等现象,并改善治疗效果。
{"title":"Lung cancer mortality trends and disparities: A cross-sectional analysis 1999–2020","authors":"Sabrina Soin ,&nbsp;Ramzi Ibrahim ,&nbsp;Rebecca Wig ,&nbsp;Numaan Mahmood ,&nbsp;Hoang Nhat Pham ,&nbsp;Enkhtsogt Sainbayar ,&nbsp;João Paulo Ferreira ,&nbsp;Roger Y. Kim ,&nbsp;See-Wei Low","doi":"10.1016/j.canep.2024.102652","DOIUrl":"10.1016/j.canep.2024.102652","url":null,"abstract":"<div><h3>Background</h3><p>Lung cancer remains a leading cause of morbidity and mortality in the United States. Given the importance of epidemiological insight on lung cancer outcomes as the foundation for targeted interventions, we aimed to examine lung cancer death trends in the United States in the recent 22-year period, exploring demographic disparities and yearly mortality shifts.</p></div><div><h3>Methods</h3><p>Mortality information was obtained from the CDC Wide-ranging Online Data for Epidemiologic Research database from the years 1999–2020. Demographic information included age, sex, race or ethnicity, and area of residence. We performed log-linear regression models to assess temporal mortality shifts and calculated average annual percentage change (AAPC) and compared age-adjusted mortality rates (AAMR) across demographic subpopulations.</p></div><div><h3>Results</h3><p>A total of 3,380,830 lung cancer deaths were identified. The AAMR decreased from 55.4 in 1999-31.8 in 2020 (p&lt;0.001). Males (AAMR 57.6) and non-Hispanic (NH) (AAMR 47.5) populations were disproportionately impacted compared to females (AAMR 36.0) and Hispanic (AAMR 19.1) populations, respectively. NH Black populations had the highest AAMR (48.5) despite an overall reduction in lung cancer deaths (AAPC −3.3 %) over the study period. Although non-metropolitan regions were affected by higher mortality rates, the annual decrease in mortality among metropolitan regions (AAPC −2.8 %, p&lt;0.001) was greater compared to non-metropolitan regions (AAPC −1.7 %, p&lt;0.001). Individuals living in the Western US (AAPC −3.4 %, p&lt;0.001) experienced the greatest decline in lung cancer mortality compared to other US census regions.</p></div><div><h3>Conclusions</h3><p>Our findings revealed lung cancer mortality inequalities in the US. By contextualizing these mortality shifts, we provide a larger framework of data-driven initiatives for societal and health policy changes for improving access to care, minimizing healthcare inequalities, and improving outcomes.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102652"},"PeriodicalIF":2.4,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142088414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment differences and long-term outcomes in adults and children with Ewing sarcoma 成人和儿童尤文肉瘤患者的治疗差异和长期疗效。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-23 DOI: 10.1016/j.canep.2024.102653
Omar I. Hajjaj , Lauren Corke , Caron Strahlendorf , Sarah Nicole Hamilton , Xiaolan Feng , Christine E. Simmons

Introduction

Ewing sarcoma is an aggressive malignancy primarily affecting children and adolescents. Limited research is available on treatment practices, clinical course, and survival in adults.

Methods

A multi-institution retrospective cohort study of all adults (>18 years) and children (≤18 years) with Ewing sarcoma treated in British Columbia, Canada between January 01, 2000 and December 31, 2018.

Results

One-hundred seven individuals (66 adults, 41 children) were included in the analysis. 5-year OS was 58 % in adults and 75 % in children. For individuals with local disease, 5-year OS was 74 % in adults and 84 % in children. Adult status was associated with impaired PFS (HR, 1.8; 95 % CI, 1.0 – 3.1, p=0.04) and OS (HR, 1.8; 95 % CI, 0.9 – 3.5; p=0.088). A Charlson Comorbidity Index (CCI) ≥3 was associated with impaired survival in adults and children (HR, 3.9, 95 % CI, 2.0 – 7.5; p=<0.001); baseline CCIs were not significantly different between groups. Most adults (61/66; 92 %) and all children (41/41; 100 %) received systemic treatment with no significant difference in mean lines of therapy, treatment modalities or agents. Most children received interval-compressed chemotherapy (35/41; 85 %) compared to adults (19/61; 29 %; p=<0.001). Interval-compression was not significantly associated with improved survival in adults with local disease (HR, 0.51; 95 % CI 0.1 – 2.3; p=0.373). Children more often initiated treatment within 28 days of diagnosis (31/33; 94 %) compared to adults (41/64; 64 %, p=0.001). Treatment within 28 days was associated with improved survival in the entire cohort (HR, 2.04 95 % CI, 1.1 – 3.9; p = 0.03). This association was preserved in subanalysis of individuals with local disease (HR, 5.4; 95 % CI, 1.9 – 15; p = 0.001) and only adults (HR, 5.3, 95 % CI, 1.7 – 17; p = 0.005).

Discussion

Survival for adults with Ewing sarcoma is inferior to children despite similarities in presentation, tumour characteristics and treatments. Further studies on the value of interval-compression in adults are required. Timely initation of treatment should be a priority for this disease.

简介尤文肉瘤是一种侵袭性恶性肿瘤,主要影响儿童和青少年。有关成人治疗方法、临床过程和存活率的研究十分有限:对2000年1月1日至2018年12月31日期间在加拿大不列颠哥伦比亚省接受治疗的所有成人(大于18岁)和儿童(小于18岁)尤文肉瘤患者进行多机构回顾性队列研究:177人(66名成人,41名儿童)被纳入分析。成人的5年生存率为58%,儿童为75%。对于患有局部疾病的患者,5年生存率成人为74%,儿童为84%。成人患者的 PFS(HR,1.8;95 % CI,1.0 - 3.1,p=0.04)和 OS(HR,1.8;95 % CI,0.9 - 3.5;p=0.088)受损。Charlson合并症指数(CCI)≥3与成人和儿童的生存率下降有关(HR,3.9;95 % CI,2.0 - 7.5;p=讨论:尽管表现、肿瘤特征和治疗方法相似,但成人尤文肉瘤患者的生存率却低于儿童患者。需要进一步研究间期压缩对成人的价值。及时开始治疗应是这种疾病的首要任务。
{"title":"Treatment differences and long-term outcomes in adults and children with Ewing sarcoma","authors":"Omar I. Hajjaj ,&nbsp;Lauren Corke ,&nbsp;Caron Strahlendorf ,&nbsp;Sarah Nicole Hamilton ,&nbsp;Xiaolan Feng ,&nbsp;Christine E. Simmons","doi":"10.1016/j.canep.2024.102653","DOIUrl":"10.1016/j.canep.2024.102653","url":null,"abstract":"<div><h3>Introduction</h3><p>Ewing sarcoma is an aggressive malignancy primarily affecting children and adolescents. Limited research is available on treatment practices, clinical course, and survival in adults.</p></div><div><h3>Methods</h3><p>A multi-institution retrospective cohort study of all adults (&gt;18 years) and children (≤18 years) with Ewing sarcoma treated in British Columbia, Canada between January 01, 2000 and December 31, 2018.</p></div><div><h3>Results</h3><p>One-hundred seven individuals (66 adults, 41 children) were included in the analysis. 5-year OS was 58 % in adults and 75 % in children. For individuals with local disease, 5-year OS was 74 % in adults and 84 % in children. Adult status was associated with impaired PFS (HR, 1.8; 95 % CI, 1.0 – 3.1, p=0.04) and OS (HR, 1.8; 95 % CI, 0.9 – 3.5; p=0.088). A Charlson Comorbidity Index (CCI) ≥3 was associated with impaired survival in adults and children (HR, 3.9, 95 % CI, 2.0 – 7.5; p=&lt;0.001); baseline CCIs were not significantly different between groups. Most adults (61/66; 92 %) and all children (41/41; 100 %) received systemic treatment with no significant difference in mean lines of therapy, treatment modalities or agents. Most children received interval-compressed chemotherapy (35/41; 85 %) compared to adults (19/61; 29 %; p=&lt;0.001). Interval-compression was not significantly associated with improved survival in adults with local disease (HR, 0.51; 95 % CI 0.1 – 2.3; p=0.373). Children more often initiated treatment within 28 days of diagnosis (31/33; 94 %) compared to adults (41/64; 64 %, p=0.001). Treatment within 28 days was associated with improved survival in the entire cohort (HR, 2.04 95 % CI, 1.1 – 3.9; p = 0.03). This association was preserved in subanalysis of individuals with local disease (HR, 5.4; 95 % CI, 1.9 – 15; p = 0.001) and only adults (HR, 5.3, 95 % CI, 1.7 – 17; p = 0.005).</p></div><div><h3>Discussion</h3><p>Survival for adults with Ewing sarcoma is inferior to children despite similarities in presentation, tumour characteristics and treatments. Further studies on the value of interval-compression in adults are required. Timely initation of treatment should be a priority for this disease.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102653"},"PeriodicalIF":2.4,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124001322/pdfft?md5=cb2830656cd6fd1fe304d6e6e5dc7017&pid=1-s2.0-S1877782124001322-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of prostate, colorectal and male breast cancers in relation with statins and testosterone replacement therapy: SEER-Medicare 2007–2015 前列腺癌、结肠直肠癌和男性乳腺癌发病率与他汀类药物和睾酮替代疗法的关系:SEER-Medicare 2007-2015。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-21 DOI: 10.1016/j.canep.2024.102633
Omer Abdelgadir , Maryam R. Hussain , Efstathia Polychronopoulou , Konstantinos K. Tsilidis , Laith Alzweri , Alejandro Villasante-Tezanos , Jacques Baillargeon , Steven Canfield , Yong-Fang Kuo , David S. Lopez

Introduction

Statins and testosterone replacement therapy (TTh) have been inconsistently associated with a reduced risk of hormone-related cancers (HRCs, prostate [PCa], colorectal [CRC], and male breast cancers [BrCa]). Yet, the joint association of statins and TTh with the incidence of these cancers, and whether these associations vary by race, remains poorly understood. The objective of this retrospective cohort study is to examine the independent and joint effects of pre-diagnostic use of statins and TTh on the risk of HRCs, including PCa, CRC, and male BrCa.

Materials

and Methods: In 105,690 men (≥65 yrs) identified using the SEER-Medicare 2007–2015 data, we identified 82,578 White and 10,256 Black men. Pre-diagnostic prescription of statins and TTh was ascertained for this analysis and categorized into four groups (Neither users, statins alone, TTh alone and Dual users). Multivariable Time-varying Cox proportional hazards and Accelerated Failure Time (AFT) models were performed.

Results

We found inverse joint associations of statins and TTh with incident HRCs before (aHR: 0.39; 95 % CI: 0.35–0.44) and after 3 years of follow-up (aHR: 0.74; 95 % CI: 0.67–0.82). This included a lower risk for advanced stage HRC (only <3 years follow-up). Similar joint associations were identified with incident PCa, aggressive PCa, incident CRC, and its specific right- and left-sided CRC (only <3 years follow-up). In general, the inverse associations persisted among White (mainly <3 years follow-up) and Black men (high-grade HRC and <3 years follow-up). Findings from the AFT analysis were similar.

Discussion

Pre-diagnostic use of statins and TTh were, independently and jointly, associated with reduced risks of HRC and specific cancer sites at three years of follow-up overall, and among White and Black men. Greatest associations of HRCs risk reduction were observed among dual users (statins plus TTh). Further studies are needed to validate these findings, including larger samples of Black men, and male BrCa sites.

简介:他汀类药物和睾酮替代疗法(TTh他汀类药物和睾酮替代疗法(TTh)与荷尔蒙相关癌症(HRCs、前列腺癌[PCa]、结肠直肠癌[CRC]和男性乳腺癌[BrCa])风险降低的关系并不一致。然而,人们对他汀类药物和TTh与这些癌症发病率之间的关系,以及这些关系是否因种族而异仍知之甚少。这项回顾性队列研究的目的是检测诊断前使用他汀类药物和TTh对包括PCa、CRC和男性BrCa在内的人类癌症风险的独立和联合影响:在使用 SEER-Medicare 2007-2015 年数据确定的 105,690 名男性(≥65 岁)中,我们确定了 82,578 名白人男性和 10,256 名黑人男性。本次分析确定了诊断前他汀类药物和 TTh 的处方,并将其分为四组(均不使用、仅使用他汀类、仅使用 TTh 和双重使用者)。采用多变量时变考克斯比例危害和加速衰竭时间(AFT)模型进行分析:结果:我们发现他汀类药物和 TTh 在随访前(aHR:0.39;95 % CI:0.35-0.44)和随访 3 年后(aHR:0.74;95 % CI:0.67-0.82)与 HRCs 发生率呈负相关。这包括较低的晚期 HRC 风险(仅讨论):诊断前使用他汀类药物和 TTh 单独或共同与随访 3 年后患 HRC 和特定癌症部位的风险降低有关,在白人和黑人男性中也是如此。在双重使用者(他汀类药物加 TTh)中观察到的 HRC 风险降低相关性最大。还需要进一步的研究来验证这些发现,包括对更多的黑人男性样本和男性癌症部位进行研究。
{"title":"Incidence of prostate, colorectal and male breast cancers in relation with statins and testosterone replacement therapy: SEER-Medicare 2007–2015","authors":"Omer Abdelgadir ,&nbsp;Maryam R. Hussain ,&nbsp;Efstathia Polychronopoulou ,&nbsp;Konstantinos K. Tsilidis ,&nbsp;Laith Alzweri ,&nbsp;Alejandro Villasante-Tezanos ,&nbsp;Jacques Baillargeon ,&nbsp;Steven Canfield ,&nbsp;Yong-Fang Kuo ,&nbsp;David S. Lopez","doi":"10.1016/j.canep.2024.102633","DOIUrl":"10.1016/j.canep.2024.102633","url":null,"abstract":"<div><h3>Introduction</h3><p>Statins and testosterone replacement therapy (TTh) have been inconsistently associated with a reduced risk of hormone-related cancers (HRCs, prostate [PCa], colorectal [CRC], and male breast cancers [BrCa]). Yet, the joint association of statins and TTh with the incidence of these cancers, and whether these associations vary by race, remains poorly understood. The objective of this retrospective cohort study is to examine the independent and joint effects of pre-diagnostic use of statins and TTh on the risk of HRCs, including PCa, CRC, and male BrCa.</p></div><div><h3>Materials</h3><p><em>and Methods:</em> In 105,690 men (≥65 yrs) identified using the SEER-Medicare 2007–2015 data, we identified 82,578 White and 10,256 Black men. Pre-diagnostic prescription of statins and TTh was ascertained for this analysis and categorized into four groups (Neither users, statins alone, TTh alone and Dual users). Multivariable Time-varying Cox proportional hazards and Accelerated Failure Time (AFT) models were performed.</p></div><div><h3>Results</h3><p>We found inverse joint associations of statins and TTh with incident HRCs before (aHR: 0.39; 95 % CI: 0.35–0.44) and after 3 years of follow-up (aHR: 0.74; 95 % CI: 0.67–0.82). This included a lower risk for advanced stage HRC (only &lt;3 years follow-up). Similar joint associations were identified with incident PCa, aggressive PCa, incident CRC, and its specific right- and left-sided CRC (only &lt;3 years follow-up). In general, the inverse associations persisted among White (mainly &lt;3 years follow-up) and Black men (high-grade HRC and &lt;3 years follow-up). Findings from the AFT analysis were similar.</p></div><div><h3>Discussion</h3><p>Pre-diagnostic use of statins and TTh were, independently and jointly, associated with reduced risks of HRC and specific cancer sites at three years of follow-up overall, and among White and Black men. Greatest associations of HRCs risk reduction were observed among dual users (statins plus TTh). Further studies are needed to validate these findings, including larger samples of Black men, and male BrCa sites.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102633"},"PeriodicalIF":2.4,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival analysis of gynecological cancers in Southeast China, 2011–2020: A population-based study 2011-2020年中国东南地区妇科癌症生存率分析:基于人口的研究
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-20 DOI: 10.1016/j.canep.2024.102641
Sufang Deng , Yan Zhou , Jie Lin , Zhisheng Xiang , Linying Liu , Ning Xie , Haijuan Yu , Yang Sun

Purpose

To analyze the survival outcomes of female patients with cervical, uterine, and ovarian cancers in Southeast China (Fujian Province) from 2011 to 2020 and to provide a reference basis for prognostic evaluation and prevention of gynecological malignancies.

Methods

The data of 5823 patients with cervical, uterine, and ovarian cancers registered in the Fujian Provincial Cancer Prevention and Control System from 2011 to 2020 were enrolled for survival analysis and further stratified by age at diagnosis and township. Survival time was calculated up to March 30, 2022, and relative survival (RS) and age-standardized RS were calculated according to the International Cancer Survival Standards (ICSS).

Results

During 2011–2015, the 5-year RS for cervical, uterine, and ovarian cancers were 64.3 %, 64.2 %, and 44.7 %, respectively, while the age-standardized 5-year RS were 56.8 %, 47.9 %, and 27.9 %, respectively. During 2016–2020, the 5-year RS for cervical, uterine, and ovarian cancers were 72.3 %, 78.9 %, and 50.8 %, respectively, while the age-standardized 5-year RS were 64.5 %, 54.6 %, and 34.2 %, respectively. The 5-year RS for cervical and ovarian cancer all declined with age, while the 5-year RS for uterine cancer was highest at 45–54 years and lowest at 75 years. In addition, survival rates were broadly higher in urban than rural areas.

Conclusion

Survival rates for cervical, uterine, and ovarian cancers have generally increased in the population covered by the Fujian Cancer Registry. However, survival rates remain lower than in developed countries. Emphasis should be placed on gynecological cancer screening and the introduction of effective treatments to improve survival rates for gynecological cancers.

目的分析2011-2020年中国东南地区(福建省)女性宫颈癌、子宫癌和卵巢癌患者的生存状况,为妇科恶性肿瘤的预后评估和预防提供参考依据。方法对2011-2020年福建省肿瘤防治系统登记的5823例宫颈癌、子宫癌和卵巢癌患者的数据进行生存分析,并按确诊年龄和乡镇进一步分层。结果2011-2015年,宫颈癌、子宫癌和卵巢癌的5年生存率分别为64.3%、64.2%和44.7%,年龄标准化5年生存率分别为56.8%、47.9%和27.9%。2016-2020 年期间,宫颈癌、子宫癌和卵巢癌的 5 年 RS 分别为 72.3 %、78.9 % 和 50.8 %,而年龄标准化的 5 年 RS 分别为 64.5 %、54.6 % 和 34.2 %。宫颈癌和卵巢癌的 5 年 RS 均随着年龄的增长而下降,而子宫癌的 5 年 RS 在 45-54 岁时最高,在 75 岁时最低。结论福建省肿瘤登记所覆盖人群的宫颈癌、子宫癌和卵巢癌存活率普遍上升。然而,生存率仍低于发达国家。应重视妇科癌症筛查,引入有效的治疗方法,以提高妇科癌症的生存率。
{"title":"Survival analysis of gynecological cancers in Southeast China, 2011–2020: A population-based study","authors":"Sufang Deng ,&nbsp;Yan Zhou ,&nbsp;Jie Lin ,&nbsp;Zhisheng Xiang ,&nbsp;Linying Liu ,&nbsp;Ning Xie ,&nbsp;Haijuan Yu ,&nbsp;Yang Sun","doi":"10.1016/j.canep.2024.102641","DOIUrl":"10.1016/j.canep.2024.102641","url":null,"abstract":"<div><h3>Purpose</h3><p>To analyze the survival outcomes of female patients with cervical, uterine, and ovarian cancers in Southeast China (Fujian Province) from 2011 to 2020 and to provide a reference basis for prognostic evaluation and prevention of gynecological malignancies.</p></div><div><h3>Methods</h3><p>The data of 5823 patients with cervical, uterine, and ovarian cancers registered in the Fujian Provincial Cancer Prevention and Control System from 2011 to 2020 were enrolled for survival analysis and further stratified by age at diagnosis and township. Survival time was calculated up to March 30, 2022, and relative survival (RS) and age-standardized RS were calculated according to the International Cancer Survival Standards (ICSS).</p></div><div><h3>Results</h3><p>During 2011–2015, the 5-year RS for cervical, uterine, and ovarian cancers were 64.3 %, 64.2 %, and 44.7 %, respectively, while the age-standardized 5-year RS were 56.8 %, 47.9 %, and 27.9 %, respectively. During 2016–2020, the 5-year RS for cervical, uterine, and ovarian cancers were 72.3 %, 78.9 %, and 50.8 %, respectively, while the age-standardized 5-year RS were 64.5 %, 54.6 %, and 34.2 %, respectively. The 5-year RS for cervical and ovarian cancer all declined with age, while the 5-year RS for uterine cancer was highest at 45–54 years and lowest at 75 years. In addition, survival rates were broadly higher in urban than rural areas.</p></div><div><h3>Conclusion</h3><p>Survival rates for cervical, uterine, and ovarian cancers have generally increased in the population covered by the Fujian Cancer Registry. However, survival rates remain lower than in developed countries. Emphasis should be placed on gynecological cancer screening and the introduction of effective treatments to improve survival rates for gynecological cancers.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102641"},"PeriodicalIF":2.4,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors and consequences of different pathways to emergency diagnosis of cancer in England: Evidence from linked national audit and cancer registration data 英格兰癌症紧急诊断不同途径的预测因素和后果:从关联的国家审计和癌症登记数据中获得的证据
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-20 DOI: 10.1016/j.canep.2024.102607
Ruth Swann , Georgios Lyratzopoulos , Greg Rubin , Lucy Elliss-Brookes , Sean McPhail

Background

Diagnosis of cancer soon after emergency care use is associated with adverse prognosis. We aimed to more precisely explore different definitions of emergency diagnosis.

Methods

For 43,383 patients in the National Cancer Diagnosis Audit and Routes to Diagnosis datasets, we defined two emergency care pathways: emergency referral (Type-A) and emergency hospital admission (Type-B). We examined patient and tumour factors associated with each pathway excluding the other, and in combination (Type-A+B), in particular their concordance and prognostic implications for short-term mortality.

Results

One in five patients (19 %) were diagnosed following emergency care use: 4 % through Type-A only, 7 % through Type-B only, and 8 % through Type-A+B. Higher co-morbidity, deprivation, advanced stage and certain cancer sites were associated with greater risk of emergency diagnosis. Concordance of emergency diagnosis pathway between Type-A and Type-B increased with age, co-morbidity and certain cancer sites. Patients with non-alarm symptoms were more likely to self-refer (Type-A) to an Emergency Department than patients with alarm symptoms. Associations with higher short-term mortality were strongest for Type-A+B.

Conclusions

We profile different pathways to emergency diagnosis and identify opportunities to improve diagnostic processes for these patients.

背景使用急诊后不久诊断出癌症与不良预后有关。我们的目的是更精确地探讨急诊诊断的不同定义。方法对于全国癌症诊断审计和诊断路径数据集中的 43383 名患者,我们定义了两种急诊路径:急诊转诊(A 型)和急诊入院(B 型)。我们研究了与每种途径相关的患者和肿瘤因素(不包括另一种途径),以及它们的组合(A+B 型),特别是它们的一致性和对短期死亡率的预后影响:其中 4% 仅为 A 型,7% 仅为 B 型,8% 为 A+B 型。共病率较高、贫困、晚期和某些癌症部位与急诊风险较大有关。随着年龄、并发症和某些癌症部位的增加,A 型和 B 型急诊诊断路径的一致性也随之增加。与有报警症状的患者相比,无报警症状的患者更有可能自我转诊(A 型)至急诊科。结论我们描述了急诊诊断的不同路径,并确定了改善这些患者诊断流程的机会。
{"title":"Predictors and consequences of different pathways to emergency diagnosis of cancer in England: Evidence from linked national audit and cancer registration data","authors":"Ruth Swann ,&nbsp;Georgios Lyratzopoulos ,&nbsp;Greg Rubin ,&nbsp;Lucy Elliss-Brookes ,&nbsp;Sean McPhail","doi":"10.1016/j.canep.2024.102607","DOIUrl":"10.1016/j.canep.2024.102607","url":null,"abstract":"<div><h3>Background</h3><p>Diagnosis of cancer soon after emergency care use is associated with adverse prognosis. We aimed to more precisely explore different definitions of emergency diagnosis.</p></div><div><h3>Methods</h3><p>For 43,383 patients in the National Cancer Diagnosis Audit and Routes to Diagnosis datasets, we defined two emergency care pathways: emergency referral (Type-A) and emergency hospital admission (Type-B). We examined patient and tumour factors associated with each pathway excluding the other, and in combination (Type-A+B), in particular their concordance and prognostic implications for short-term mortality.</p></div><div><h3>Results</h3><p>One in five patients (19 %) were diagnosed following emergency care use: 4 % through Type-A only, 7 % through Type-B only, and 8 % through Type-A+B. Higher co-morbidity, deprivation, advanced stage and certain cancer sites were associated with greater risk of emergency diagnosis. Concordance of emergency diagnosis pathway between Type-A and Type-B increased with age, co-morbidity and certain cancer sites. Patients with non-alarm symptoms were more likely to self-refer (Type-A) to an Emergency Department than patients with alarm symptoms. Associations with higher short-term mortality were strongest for Type-A+B.</p></div><div><h3>Conclusions</h3><p>We profile different pathways to emergency diagnosis and identify opportunities to improve diagnostic processes for these patients.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102607"},"PeriodicalIF":2.4,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1877782124000869/pdfft?md5=318f147b1b85cec4dfc0d6e8ade3d32d&pid=1-s2.0-S1877782124000869-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occupations and the risk of buccal mucosa cancer in Indian men: A multi-centre case-control study 印度男性的职业与罹患口腔黏膜癌的风险:一项多中心病例对照研究
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-16 DOI: 10.1016/j.canep.2024.102644
Romi Moirangthem , Bayan Hosseini , Aniket Patil , Grace Sarah George , Ankita Manjrekar , Pravin Doibale , Shruti Vishwas Golapkar , Nandkumar Panse , Manigreeva Krishnatreya , Aseem Mishra , Arjun Singh , Anil Chaturvedi , Pankaj Chaturvedi , Rajesh Dikshit , Ann Olsson , Sharayu Mhatre

Objective

This study aimed to investigate the association between lifetime occupational history and risk of buccal mucosa cancer (BMC).

Methods

We utilized a multi-centric, hospital-based case-control study across five centres of Tata Memorial Centre, Mumbai, India. Cases included men aged 20–75-years with histological confirmed primary cancer of the buccal mucosa. Visitor controls were frequency matched to cases for age (10 years interval) and current residential zone. Study participants were interviewed face-to-face. Logistic regression was performed to estimate odds ratio (OR) and 95 % confidence intervals (CI).

Results

Among ever employed males, we identified 1969 BMC cases and 2145 controls. We observed an increased risk of BMC in ‘Craft and Related Trades Workers’ (OR 1.37; 95 % CI 1.13–1.65), ‘Plant and Machine Operators and Assemblers’ (OR: 1.26; 95 % CI 1.01–1.56), and ‘Elementary Occupations’ (OR:1.33; 95 % CI 1.12–1.58). More specifically, the increased risk was observed for ‘Metal, Machinery and Related Trades Workers’, ‘Handicraft and Printing Workers’, ‘Drivers and Mobile Plant Operators’, and ‘Laborers in Mining, Construction, Manufacturing and Transport’.

Conclusion

Our findings suggest that certain occupations may be at a higher risk of BMC. Some fraction of BMC can be prevented by reducing exposure to hazardous agents used in these occupations. Further research is needed to identify which exposures are responsible for the increased risk. Moreover, tobacco control and early detection activities can be focused towards these occupations as tobacco consumption is also high in them, which may also be the reason for increased risk observed in these groups.

方法 我们在印度孟买塔塔纪念中心的五个中心开展了一项以医院为基础的多中心病例对照研究。病例包括年龄在 20-75 岁、组织学确诊为颊粘膜原发性癌症的男性。访客对照组与病例在年龄(间隔 10 年)和当前居住区域方面进行了频率匹配。研究参与者接受了面对面的访谈。结果在曾经就业的男性中,我们发现了 1969 例 BMC 病例和 2145 例对照病例。我们发现,"手工业及相关行业工人"(OR:1.37;95 % CI:1.13-1.65)、"工厂和机器操作员及装配工"(OR:1.26;95 % CI:1.01-1.56)和 "初级职业"(OR:1.33;95 % CI:1.12-1.58)的 BMC 风险增加。更具体地说,"金属、机械和相关行业工人"、"手工艺和印刷工人"、"司机和移动设备操作员 "以及 "采矿、建筑、制造和运输业工人 "的患病风险增加。通过减少接触这些职业中使用的危险制剂,可以预防部分 BMC。要确定哪些暴露是导致风险增加的原因,还需要进一步的研究。此外,烟草控制和早期检测活动可侧重于这些职业,因为这些职业的烟草消费量也很高,这也可能是这些群体中观察到的风险增加的原因。
{"title":"Occupations and the risk of buccal mucosa cancer in Indian men: A multi-centre case-control study","authors":"Romi Moirangthem ,&nbsp;Bayan Hosseini ,&nbsp;Aniket Patil ,&nbsp;Grace Sarah George ,&nbsp;Ankita Manjrekar ,&nbsp;Pravin Doibale ,&nbsp;Shruti Vishwas Golapkar ,&nbsp;Nandkumar Panse ,&nbsp;Manigreeva Krishnatreya ,&nbsp;Aseem Mishra ,&nbsp;Arjun Singh ,&nbsp;Anil Chaturvedi ,&nbsp;Pankaj Chaturvedi ,&nbsp;Rajesh Dikshit ,&nbsp;Ann Olsson ,&nbsp;Sharayu Mhatre","doi":"10.1016/j.canep.2024.102644","DOIUrl":"10.1016/j.canep.2024.102644","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to investigate the association between lifetime occupational history and risk of buccal mucosa cancer (BMC).</p></div><div><h3>Methods</h3><p>We utilized a multi-centric, hospital-based case-control study across five centres of Tata Memorial Centre, Mumbai, India. Cases included men aged 20–75-years with histological confirmed primary cancer of the buccal mucosa. Visitor controls were frequency matched to cases for age (10 years interval) and current residential zone. Study participants were interviewed face-to-face. Logistic regression was performed to estimate odds ratio (OR) and 95 % confidence intervals (CI).</p></div><div><h3>Results</h3><p>Among ever employed males, we identified 1969 BMC cases and 2145 controls. We observed an increased risk of BMC in ‘Craft and Related Trades Workers’ (OR 1.37; 95 % CI 1.13–1.65), ‘Plant and Machine Operators and Assemblers’ (OR: 1.26; 95 % CI 1.01–1.56), and ‘Elementary Occupations’ (OR:1.33; 95 % CI 1.12–1.58). More specifically, the increased risk was observed for ‘Metal, Machinery and Related Trades Workers’, ‘Handicraft and Printing Workers’, ‘Drivers and Mobile Plant Operators’, and ‘Laborers in Mining, Construction, Manufacturing and Transport’.</p></div><div><h3>Conclusion</h3><p>Our findings suggest that certain occupations may be at a higher risk of BMC. Some fraction of BMC can be prevented by reducing exposure to hazardous agents used in these occupations. Further research is needed to identify which exposures are responsible for the increased risk. Moreover, tobacco control and early detection activities can be focused towards these occupations as tobacco consumption is also high in them, which may also be the reason for increased risk observed in these groups.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102644"},"PeriodicalIF":2.4,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141992675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The contribution of rural/urban residence to incidence and survival in thymoma and thymic carcinoma, a retrospective cohort study of the SEER 2000–2020 database 农村/城市居住地对胸腺瘤和胸腺癌发病率和存活率的影响,一项 SEER 2000-2020 年数据库的回顾性队列研究。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-14 DOI: 10.1016/j.canep.2024.102645
Joseph Cascone , Bianca Ituarte , Vani Patel , Annsophia Mompoint , Mitchell Taylor , Emmanuel Daon

Objective

Rural-urban healthcare disparities have been demonstrated throughout the United States, particularly in acquiring oncologic care. In this study, we aim to discern the role of rural-urban health disparities in thymic cancer incidence and uncover potential survival disparities.

Methods

The Surveillance, Epidemiology, and End Results (SEER) 17-State database was queried for all cases of thymoma (ICD-O-3/3 codes: 8580–8585) and thymic carcinoma (8586) located in the thymus (primary site code C37.9) diagnosed between 2000 and 2020. Residence was established using SEER Rural-Urban Continuum Codes. Incidence trend modeling for rural versus urban patients was completed using Joinpoint Regression Software. Chi-square, Kaplan-Meier with log-rank testing, and Cox proportional hazards was completed using SPSS, with significance set to p <0.05.

Results

Joinpoint analysis revealed a significant growth in incidence in the urban population compared to a stagnant incidence among the rural population. Disease specific survival was higher among urban patients on univariate modeling (p = 0.010), and confirmed on multivariate analysis, whereby rural living conferred an adjusted hazard ratio of 1.263 (95 % CI 1.045–1.527; p = 0.016) in comparison to urban patients.

Conclusions

These findings demonstrate differences between thymic cancer incidence and outcomes in patients living in urban versus rural environments and demonstrate an important disparity.

目的:美国各地都存在城乡医疗差距,尤其是在获得肿瘤治疗方面。在这项研究中,我们旨在发现城乡医疗差距在胸腺癌发病率中的作用,并揭示潜在的生存差距:方法:我们在监测、流行病学和最终结果(SEER)17 州数据库中查询了 2000 年至 2020 年期间诊断出的所有胸腺瘤(ICD-O-3/3 编码:8580-8585)和胸腺癌(8586)病例(主要部位编码 C37.9)。居住地使用 SEER 农村-城市连续编码确定。使用Joinpoint回归软件完成了农村与城市患者的发病趋势建模。使用 SPSS 完成了 Chi-square、Kaplan-Meier(带对数秩检验)和 Cox 比例危险度检验,显著性设置为 p 结果:连接点分析表明,与农村人口的发病率停滞不前相比,城市人口的发病率有明显增长。在单变量模型中,城市患者的疾病特异性生存率更高(p = 0.010),多变量分析证实了这一点,与城市患者相比,农村患者的调整后危险比为 1.263(95 % CI 1.045-1.527; p = 0.016):这些研究结果表明,生活在城市和农村环境中的胸腺癌患者在发病率和预后方面存在差异,并显示出重要的差异。
{"title":"The contribution of rural/urban residence to incidence and survival in thymoma and thymic carcinoma, a retrospective cohort study of the SEER 2000–2020 database","authors":"Joseph Cascone ,&nbsp;Bianca Ituarte ,&nbsp;Vani Patel ,&nbsp;Annsophia Mompoint ,&nbsp;Mitchell Taylor ,&nbsp;Emmanuel Daon","doi":"10.1016/j.canep.2024.102645","DOIUrl":"10.1016/j.canep.2024.102645","url":null,"abstract":"<div><h3>Objective</h3><p>Rural-urban healthcare disparities have been demonstrated throughout the United States, particularly in acquiring oncologic care. In this study, we aim to discern the role of rural-urban health disparities in thymic cancer incidence and uncover potential survival disparities.</p></div><div><h3>Methods</h3><p>The Surveillance, Epidemiology, and End Results (SEER) 17-State database was queried for all cases of thymoma (ICD-O-3/3 codes: 8580–8585) and thymic carcinoma (8586) located in the thymus (primary site code C37.9) diagnosed between 2000 and 2020. Residence was established using SEER Rural-Urban Continuum Codes. Incidence trend modeling for rural versus urban patients was completed using Joinpoint Regression Software. Chi-square, Kaplan-Meier with log-rank testing, and Cox proportional hazards was completed using SPSS, with significance set to p &lt;0.05.</p></div><div><h3>Results</h3><p>Joinpoint analysis revealed a significant growth in incidence in the urban population compared to a stagnant incidence among the rural population. Disease specific survival was higher among urban patients on univariate modeling (p = 0.010), and confirmed on multivariate analysis, whereby rural living conferred an adjusted hazard ratio of 1.263 (95 % CI 1.045–1.527; p = 0.016) in comparison to urban patients.</p></div><div><h3>Conclusions</h3><p>These findings demonstrate differences between thymic cancer incidence and outcomes in patients living in urban versus rural environments and demonstrate an important disparity.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102645"},"PeriodicalIF":2.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors 免疫检查点抑制剂时代转移性肾细胞癌患者总生存期的变化
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-14 DOI: 10.1016/j.canep.2024.102639
Arjab Adhikari , Supriya Sapkota , Sopiko Gogia , Ojbindra KC

Background

The advent of immune checkpoint inhibitors (ICI) has brought about a significant transformation in the treatment of immunogenic tumors. On November 23, 2015, the United States Food and Drug Administration approved Nivolumab to treat metastatic renal cell carcinoma (RCC). We aimed to assess potential changes in the survival rates of patients with metastatic RCC at a population level after the approval of Nivolumab.

Methods

We used data from the latest version of the Surveillance, Epidemiology, and End Results (SEER) database which encompasses data up to the year 2020. We included patients with age ≥ 20 years who were diagnosed with ‘distant’ RCC from 2011 through 2020. Based on the approval of Nivolumab, the period from 2011 to 2020 was further grouped into 2011–2015 (pre-ICI era) and 2016–2020 (ICI era).

Results

The median overall survival (OS) was 8 months in the pre-ICI era compared to 11 months in the ICI era (log-rank test, χ2 = 102.53, p < 0.001). Patients diagnosed with metastatic RCC in the ICI era had a significantly lower risk of dying [Cox proportional Hazard Ratio of 0.77, 95 % CI (0.74–0.80)] compared to patients diagnosed in the pre-ICI era. Additionally, patients under the age of 75 had a lower risk of death compared to those aged 75 years or older. Patients who received chemotherapy (systemic therapy), radiotherapy, or surgery faced a significantly lower risk of mortality. Individuals with metastasis to the brain, bone, liver, or lung had a significantly higher risk of death than those without metastasis to these locations. Marital status also played a role, as married individuals had a significantly lower risk of death compared to those who were divorced, separated, or widowed at the time of diagnosis. Furthermore, income level influenced survival, with patients earning a median annual household income of more than USD 75,000 exhibiting a significantly lower risk of mortality compared to those earning between USD 50,000 and USD 74,000. There was no significant difference in survival observed between non-Hispanic blacks and non-Hispanic whites.

Conclusion

The advent of immune checkpoint inhibitors has led to a substantial improvement in the median overall survival of individuals diagnosed with metastatic renal cell carcinoma.

背景免疫检查点抑制剂(ICI)的出现给免疫原性肿瘤的治疗带来了重大变革。2015 年 11 月 23 日,美国食品和药物管理局批准 Nivolumab 用于治疗转移性肾细胞癌(RCC)。我们的目的是评估Nivolumab获批后,转移性RCC患者的生存率在人群水平上可能发生的变化。我们纳入了从2011年到2020年被诊断为 "远处 "RCC的年龄≥20岁的患者。结果前ICI时代的中位总生存期(OS)为8个月,而ICI时代为11个月(log-rank检验,χ2 = 102.53,p <0.001)。与ICI前时代确诊的患者相比,ICI时代确诊的转移性RCC患者的死亡风险显著降低[Cox比例危险比为0.77,95 % CI (0.74-0.80)]。此外,与 75 岁或以上的患者相比,75 岁以下患者的死亡风险较低。接受化疗(全身治疗)、放疗或手术的患者死亡风险明显降低。转移至脑、骨、肝或肺部的患者的死亡风险明显高于未转移至这些部位的患者。婚姻状况也有影响,与诊断时已离婚、分居或丧偶的人相比,已婚者的死亡风险明显较低。此外,收入水平也影响存活率,家庭年收入中位数超过75,000美元的患者的死亡风险明显低于收入在50,000至74,000美元之间的患者。非西班牙裔黑人和非西班牙裔白人的生存率没有明显差异。结论免疫检查点抑制剂的出现大大提高了转移性肾细胞癌患者的中位总生存率。
{"title":"Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors","authors":"Arjab Adhikari ,&nbsp;Supriya Sapkota ,&nbsp;Sopiko Gogia ,&nbsp;Ojbindra KC","doi":"10.1016/j.canep.2024.102639","DOIUrl":"10.1016/j.canep.2024.102639","url":null,"abstract":"<div><h3>Background</h3><p>The advent of immune checkpoint inhibitors (ICI) has brought about a significant transformation in the treatment of immunogenic tumors. On November 23, 2015, the United States Food and Drug Administration approved Nivolumab to treat metastatic renal cell carcinoma (RCC). We aimed to assess potential changes in the survival rates of patients with metastatic RCC at a population level after the approval of Nivolumab.</p></div><div><h3>Methods</h3><p>We used data from the latest version of the Surveillance, Epidemiology, and End Results (SEER) database which encompasses data up to the year 2020. We included patients with age ≥ 20 years who were diagnosed with ‘distant’ RCC from 2011 through 2020. Based on the approval of Nivolumab, the period from 2011 to 2020 was further grouped into 2011–2015 (pre-ICI era) and 2016–2020 (ICI era).</p></div><div><h3>Results</h3><p>The median overall survival (OS) was 8 months in the pre-ICI era compared to 11 months in the ICI era (log-rank test, χ2 = 102.53, p &lt; 0.001). Patients diagnosed with metastatic RCC in the ICI era had a significantly lower risk of dying [Cox proportional Hazard Ratio of 0.77, 95 % CI (0.74–0.80)] compared to patients diagnosed in the pre-ICI era. Additionally, patients under the age of 75 had a lower risk of death compared to those aged 75 years or older. Patients who received chemotherapy (systemic therapy), radiotherapy, or surgery faced a significantly lower risk of mortality. Individuals with metastasis to the brain, bone, liver, or lung had a significantly higher risk of death than those without metastasis to these locations. Marital status also played a role, as married individuals had a significantly lower risk of death compared to those who were divorced, separated, or widowed at the time of diagnosis. Furthermore, income level influenced survival, with patients earning a median annual household income of more than USD 75,000 exhibiting a significantly lower risk of mortality compared to those earning between USD 50,000 and USD 74,000. There was no significant difference in survival observed between non-Hispanic blacks and non-Hispanic whites.</p></div><div><h3>Conclusion</h3><p>The advent of immune checkpoint inhibitors has led to a substantial improvement in the median overall survival of individuals diagnosed with metastatic renal cell carcinoma.</p></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"92 ","pages":"Article 102639"},"PeriodicalIF":2.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141985776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to comments on: “Cancer incidence in ELSA-Brasil: making the case for Population Based Cancer Registries in Brazil” 对有关评论的答复:对 "ELSA-Brasil 的癌症发病率:为巴西基于人口的癌症登记提供依据 "的评论意见的答复。
IF 2.4 3区 医学 Q3 ONCOLOGY Pub Date : 2024-08-13 DOI: 10.1016/j.canep.2024.102637
Alexandra Dias Moreira , Sara Teles de Menezes , Lidyane V. Camelo , Sandhi Maria Barreto
{"title":"Response to comments on: “Cancer incidence in ELSA-Brasil: making the case for Population Based Cancer Registries in Brazil”","authors":"Alexandra Dias Moreira ,&nbsp;Sara Teles de Menezes ,&nbsp;Lidyane V. Camelo ,&nbsp;Sandhi Maria Barreto","doi":"10.1016/j.canep.2024.102637","DOIUrl":"10.1016/j.canep.2024.102637","url":null,"abstract":"","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102637"},"PeriodicalIF":2.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Epidemiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1